Drug Approval | August 05, 2021
Combinations of Sputnik V component with other vaccines demonstrate favourable results: RDIF
AstraZeneca, Sinopharm and Moderna were part of the study
AstraZeneca, Sinopharm and Moderna were part of the study
Five seats reserved for Wards of COVID warriors in central MBBS admission
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
Subscribe To Our Newsletter & Stay Updated
